MTSEA (Synonyms: 2-Aminoethyl methanethiosulfonate, Methanethiosulfonate Ethylammonium) |
Catalog No.GC44252 |
MTSEA is a sulfhydryl-reactive compound that modifies free cysteine residues to produce a positively charged side chain approximately the size of lysine.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 16599-33-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MTSEA [(2-aminoethyl) methanethiosulfonate] is a cysteine modifying agent [1], cysteine's sulfhydral side chain (-SH) can form a covalent disulfide bond with sulfur in the MTSEA reagent [2].
MTSEA was used to demonstrate the presence of a water-accessible cysteine within the binding-site crevice of the human dopamine D2 receptor [3]. MTSEA was demonstrated rotation of TM6 (upon receptor activation) by the appearance of an MTSEA-accessible cysteine in a constitutively active mutant of the β2-adrenergic receptor not accessible in the wild-type receptor [4]. The effect of MTSEA on ligand binding, in conjunction with site-directed mutagenesis, was used to define intramolecular contacts in the neurokinin-2 tachykinin receptor [5].
References:
[1]. Choi YB, Tenneti L, Le DA, Ortiz J, Bai G, Chen HS, Lipton SA. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nature neuroscience. 2000 Jan;3(1):15-21.
[2]. O'Reilly JP, Shockett PE. Time-and state-dependent effects of methanethiosulfonate ethylammonium (MTSEA) exposure differ between heart and skeletal muscle voltage-gated Na+ channels. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2012 Mar 1;1818(3):443-7.
[3]. Javitch JA, Li X, Kaback J, Karlin A. A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. Proceedings of the National Academy of Sciences. 1994 Oct 25;91(22):10355-9.
[4]. Rasmussen SG, Jensen AD, Liapakis G, Ghanouni P, Javitch JA, Gether U. Mutation of a highly conserved aspartic acid in the β2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. Molecular pharmacology. 1999 Jul 1;56(1):175-84.
[5]. Bhogal N, Blaney FE, Ingley PM, Rees J, Findlay JB. Evidence for the proximity of the extreme N-terminus of the neurokinin-2 (NK2) tachykinin receptor to cys167 in the putative fourth transmembrane helix. Biochemistry. 2004 Mar 23;43(11):3027-38.
Cas No. | 16599-33-0 | SDF | |
Synonyms | 2-Aminoethyl methanethiosulfonate, Methanethiosulfonate Ethylammonium | ||
Canonical SMILES | NCCSS(C)(=O)=O.Br | ||
Formula | C3H9NO2S2•HBr | M.Wt | 236.1 |
Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.2355 mL | 21.1775 mL | 42.3549 mL |
5 mM | 0.8471 mL | 4.2355 mL | 8.471 mL |
10 mM | 0.4235 mL | 2.1177 mL | 4.2355 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 25 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *